Research programmes

Follow a programme’s mechanism, development history and experimental evidence.

ProteostasisHuman study

RTR242 lysosomal autophagy programme

Retro Biosciences

Retro Biosciences is testing oral RTR242 in an Australian Phase 1 safety trial. The compound is intended to restore lysosomal acidity; no human efficacy results have been published.

Cells · HumansRead dossier
ReprogrammingHuman study

ER-100

Life Biosciences

ER-100 is an OSK partial-reprogramming gene therapy in an open-label Phase 1 eye study. Its developer reports 56-day safety observations in three glaucoma patients and exploratory visual-field changes in two.

Cells · Animals · HumansRead dossier
AI discoveryPublished human results

Rentosertib

Insilico Medicine

Rentosertib connects AI-assisted target selection and molecular design with published lung-disease trial results. A September 2026 analysis examined ageing clocks in stored samples. The developer also announced first dosing in a larger Phase 3 study; the medicine remains experimental.

Cells · Animals · HumansRead dossier
ReprogrammingPreclinical research

NewLimit epigenetic reprogramming

NewLimit

NewLimit is screening reprogramming payloads for liver, vascular and immune cells. Its October 2026 update reports large-animal studies, additional screening and manufacturing scale-up; no human treatment results.

Cells · AnimalsRead dossier
ReprogrammingLaboratory research

Retro cellular reprogramming

Retro Biosciences

Retro's reprogramming portfolio includes stem-cell and tissue approaches. Its collaboration with OpenAI has reported engineered transcription factors that improve pluripotency-marker expression in human cells. That laboratory result does not establish a clinical reprogramming therapy or additional years of human life.

ReprogrammingPreclinical research

Shift cellular rejuvenation

Shift Bioscience

Shift searches for interventions that alter age-associated cell states. Its public portfolio separates the single-factor SB000 laboratory work from an SB101 antifibrotic siRNA programme with company-reported mouse evidence. Neither was verified as a human clinical rejuvenation study.

Cells · AnimalsRead dossier
ReprogrammingLaboratory research

Altos cellular rejuvenation

Altos Labs

Altos studies how cells regain health and resilience, combining experimental biology with computational modelling. This is an organisation-level research programme. Foundational cell and animal studies support its approach; no named clinical rejuvenation candidate or human outcome was verified in this dossier.

Cells · AnimalsRead dossier
SenescenceDiscontinued

UBX1325 / foselutoclax

UNITY Biotechnology

UNITY tested a senolytic eye injection against an established treatment for diabetic macular oedema. ASPIRE missed its prespecified primary comparison. A later analysis reported noninferiority at week 36. UNITY subsequently closed its operating business.

Cells · Animals · HumansRead dossier
SenescencePublished human results

Dasatinib and quercetin human research

Mayo-origin senolytic research and collaborating academic groups

Academic groups are testing whether a drug combination can remove senescent cells and improve particular diseases. Human results include tissue-marker changes, a negative primary bone endpoint and a small positive liver-fibrosis trial. These are distinct experiments with different populations and outcomes.

Cells · Animals · HumansRead dossier
DeliveryPreclinical research

RJB-0402 liver-directed FGF21 gene therapy

Rejuvenate Bio

Rejuvenate Bio proposes using the liver to produce a circulating protein intended to affect diseased heart tissue. RJB-0402 is aimed at arrhythmogenic cardiomyopathy. Public sources document preclinical work and trial preparation, but do not verify a human intervention study start.

Cells · AnimalsRead dossier
RegenerationHuman study

LYG-LIV-001 ectopic liver tissue

LyGenesis

LyGenesis transplants donor liver cells into abdominal lymph nodes, where it aims to grow auxiliary liver tissue. Human testing began in 2024. A subsequent safety review supported continuation, while detailed human efficacy results remain unverified in the sources checked.

Animals · HumansRead dossier
RegenerationPublished human results

EGEN-2784 engineered pig kidney

eGenesis

eGenesis engineers pig kidneys to address immune incompatibility and pathogen risks in transplantation. Expanded access has supplied early human evidence. A formal trial remains a planned next step, with its proposed start distinguished from the evidence already reported.

Cells · Animals · HumansRead dossier
MeasurementHuman study

XPRIZE Healthspan measurement and trials

XPRIZE Foundation and participating research teams

XPRIZE Healthspan organises a competition around improvements in muscle, cognitive and immune function. Twenty teams entered the finals in August 2026. Its contribution is a shared trial and measurement framework; finalist selection is not evidence that a competing intervention has achieved the prize's target.

SenescencePreclinical research

Senolytic CAR T cells

Academic collaborations at Memorial Sloan Kettering and Cold Spring Harbor Laboratory

Researchers have engineered T cells to recognise uPAR, a surface protein associated with senescence. Mouse studies test whether clearing these cells improves metabolism and intestinal function.

Cells · AnimalsRead dossier
DeliveryPreclinical research

Liver mRNA immune restoration

Broad Institute, MIT and academic collaborators

A mouse study uses liver-directed mRNA to supply immune signals. The research tests a temporary change in immune function.

The database follows selected programmes. An entry’s stage describes the evidence and development recorded here; it does not rate a treatment for personal use.

Search the publication

Search programme histories and research articles.